Influenza A virus H5N1 vaccine - NuGenerex Immuno-Oncology
Alternative Names: AE 443p; AE AI vaccine; H5N1 virus vaccine - Generex Biotechnology; H5N1 virus vaccine - NuGenerex Immuno-Oncology; Influenza peptide vaccines - NuGenerex Immuno-Oncology; Pandemic influenza virus vaccine - NuGenerex Immuno-Oncology/University of RochesterLatest Information Update: 16 Jan 2019
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in Lebanon (Parenteral)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral)
- 08 Feb 2017 Influenza A virus H5N1 vaccine - Antigen Express is available for licensing as of 08 Feb 2017. http://www.antigenexpress.com/ (Antigen Express pipeline, February 2017)